Cargando…

Who should be prioritised for COVID-19 vaccination?

The development of COVID-19 vaccines is occurring at a rapid pace, with the potential for a vaccine to be available within 6 months. So who should be prioritized for vaccination when in the first instance, there will be insufficient supply to meet demand? There is no doubt that health-care workers i...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, Fiona M, Greenwood, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078651/
https://www.ncbi.nlm.nih.gov/pubmed/33141000
http://dx.doi.org/10.1080/21645515.2020.1827882
_version_ 1783685086238998528
author Russell, Fiona M
Greenwood, Brian
author_facet Russell, Fiona M
Greenwood, Brian
author_sort Russell, Fiona M
collection PubMed
description The development of COVID-19 vaccines is occurring at a rapid pace, with the potential for a vaccine to be available within 6 months. So who should be prioritized for vaccination when in the first instance, there will be insufficient supply to meet demand? There is no doubt that health-care workers in all settings should be vaccinated first, but who comes next will be a complex decision based on local epidemiology, societal values, and the ability of the vaccines to prevent both severe disease and to reduce transmission thereby eliciting herd protection. The decision on who to vaccinate should be equitable, highly contextualized, and based on the property of each vaccine. In some settings, the elderly may be prioritized, in others, it may be the population most likely to get infected and responsible for community spread. To support decision-making on who to be prioritized for vaccination requires urgent additional research on the epidemiology of COVID-19; preexisting immunity and who is responsible for transmission in a variety of settings; the safety, immunogenicity, and efficacy of COVID-19 vaccines in children and pregnant women; and determining whether COVID-19 vaccines prevent asymptomatic infection and transmission.
format Online
Article
Text
id pubmed-8078651
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-80786512021-05-13 Who should be prioritised for COVID-19 vaccination? Russell, Fiona M Greenwood, Brian Hum Vaccin Immunother Commentary The development of COVID-19 vaccines is occurring at a rapid pace, with the potential for a vaccine to be available within 6 months. So who should be prioritized for vaccination when in the first instance, there will be insufficient supply to meet demand? There is no doubt that health-care workers in all settings should be vaccinated first, but who comes next will be a complex decision based on local epidemiology, societal values, and the ability of the vaccines to prevent both severe disease and to reduce transmission thereby eliciting herd protection. The decision on who to vaccinate should be equitable, highly contextualized, and based on the property of each vaccine. In some settings, the elderly may be prioritized, in others, it may be the population most likely to get infected and responsible for community spread. To support decision-making on who to be prioritized for vaccination requires urgent additional research on the epidemiology of COVID-19; preexisting immunity and who is responsible for transmission in a variety of settings; the safety, immunogenicity, and efficacy of COVID-19 vaccines in children and pregnant women; and determining whether COVID-19 vaccines prevent asymptomatic infection and transmission. Taylor & Francis 2020-11-03 /pmc/articles/PMC8078651/ /pubmed/33141000 http://dx.doi.org/10.1080/21645515.2020.1827882 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Commentary
Russell, Fiona M
Greenwood, Brian
Who should be prioritised for COVID-19 vaccination?
title Who should be prioritised for COVID-19 vaccination?
title_full Who should be prioritised for COVID-19 vaccination?
title_fullStr Who should be prioritised for COVID-19 vaccination?
title_full_unstemmed Who should be prioritised for COVID-19 vaccination?
title_short Who should be prioritised for COVID-19 vaccination?
title_sort who should be prioritised for covid-19 vaccination?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078651/
https://www.ncbi.nlm.nih.gov/pubmed/33141000
http://dx.doi.org/10.1080/21645515.2020.1827882
work_keys_str_mv AT russellfionam whoshouldbeprioritisedforcovid19vaccination
AT greenwoodbrian whoshouldbeprioritisedforcovid19vaccination